The investment comes as the company brought in new pharmaceutical clients, formed new partnerships and added to its leadership team. Shanda Group and AmerisourceBergen’s AB Health Ventures led the investment, according to an Oct. 25 WhizAI news release.
“WhizAI began with the vision to democratize business insights for life sciences and healthcare, ensuring analytics is for everyone. Our momentum in 2022 demonstrates that our vision and domain-centric approach is preferred by our clients,” WhizAi co-founder and CEO Rohit Vashisht said. “We’re excited to see how the market has responded to our vision for analytics to be augmented with artificial intelligence and natural language technology.”
